2-Hydroxy-2-methylpropiophenone, also known as 2-hydroxyisobutyrophenone, is a chemical compound with the formula C10H12O2. It is a white solid that is soluble in organic solvents. It is a precursor to various pharmaceuticals, including antihistamines, anticonvulsants, and analgesics. The compound is typically synthesized via Friedel-Crafts acylation of phenol with isobutyryl chloride. Research into 2-hydroxy-2-methylpropiophenone focuses on its potential medicinal properties. Studies have explored its anti-inflammatory, antioxidant, and anticancer effects. It is also being investigated for its potential in the treatment of neurological disorders such as Parkinson's disease. Its biological activity arises from its ability to interact with various enzymes and receptors in the body. The compound has been shown to inhibit the activity of certain enzymes, such as cyclooxygenase, which plays a role in inflammation.'
2-hydroxy-2-methylpropiophenone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 81984 |
| CHEMBL ID | 3187850 |
| SCHEMBL ID | 21310 |
| MeSH ID | M0473769 |
| Synonym |
|---|
| AC-18357 |
| unii-z0lrg273ad |
| ec 231-272-0 |
| benzoyl isopropanol |
| z0lrg273ad , |
| nsc 401744 |
| 2-hydroxy-2-methyl-1-phenyl-1-propanone |
| einecs 231-272-0 |
| 1-propanone, 2-hydroxy-2-methyl-1-phenyl- |
| 2-hydroxy-2-methylpropiophenone |
| 7473-98-5 |
| 1-phenyl-2-hydroxy-2-methylpropan-1-one |
| nsc-401744 |
| nsc401744 |
| 2-hydroxy-2-methylpropiophenone, 97% |
| FT-0694516 |
| H0991 |
| 2-benzoyl-2-propanol |
| 2-hydroxy-2-methyl-1-phenylpropan-1-one |
| A838215 |
| 2-hydroxy-2-methyl-1-phenyl-propan-1-one;2-hydroxy-2-methylpropiophenone |
| 2-hydroxy-2-methyl propiophenone |
| 2-hydroxy-2-methyl-1-phenyl propanone |
| cas-7473-98-5 |
| NCGC00256283-01 |
| tox21_301675 |
| dtxsid8044830 , |
| dtxcid6024830 |
| AKOS015890573 |
| SCHEMBL21310 |
| benzoyl isopropanol [inci] |
| hydroxy-2-methyl-1-phenyl-1-propanone, 2- |
| darocure 1173 |
| 2-hydroxy-2-methyl-1-phenyl-propan-1-one |
| 2-hydroxy-iso-butyrophenone |
| 2-hydroxy-2-methyl-1-phenyl propane-1-on |
| 2-hydroxy-2-methyl-1-phenyl-propane-1-on |
| 2-hydroxy-isobutyrophenone |
| 2-hydroxy-2,2-dimethylacetophenone |
| 2-hydroxy-2-methyl-1-phenyl-propane-1-one |
| 1-phenyl-2-hydroxy-2-methyl-1-propanone |
| W-104412 |
| DS-2389 |
| CHEMBL3187850 |
| mfcd00040710 |
| uv1173 |
| Q27294844 |
| iht-pi 1173 2-hydroxy-2-methylpropiophenone |
| E80394 |
| EN300-198217 |
| CS-W017909 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 48.9662 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 54.7229 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (48.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||